Who we are
Oncolix, Inc. (Oncolix) is a clinical-stage
bio-pharmaceutical company based in Houston, Texas. The company is
developing Prolanta™, a targeted therapeutic protein for the treatment
of ovarian, breast and other cancers. The Company has a US FDA-cleared
IND to commence human testing of Prolanta™ in our first indication, the
treatment of ovarian cancer.
Prolanta has been granted Orphan Drug status by the FDA for ovarian
cancer type, which may allow an accelerated regulatory approval by the
FDA, reduced filing fees, federal tax credits and marketing exclusivity.
In addition to ovarian cancer, there is strong preclinical evidence
Prolanta will be effective in breast, prostate and other cancers.